Healthesystems is attending the National Council of Self-Insurers’ conference, which brings together professionals from companies who self-insure their workers’ compensation.
Healthesystems is a proud sponsor and will be attending along with exhibiting at the American Association of State Compensation Insurance Funds conference for workers’ compensation insurance professionals.
Approval Date: Dec 2025
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, this approval is for a first-time generic
Approval Date: Nov 2025
Indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern. This approval is for a first-time generic
Approval Date: Oct 2025
Indicated for the treatment of hypertension to lower blood pressure, a new oral solution formulation of this drug is now available
Approval Date: Sep 2025
A lidocaine and amide local anesthetic patch indicated for the relief of pain associated with post-herpetic neuralgia (shingles pain)
Approval Date: Sep 2025
A biosimilar to Prolia®, this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more
Approval Date: Sep 2025
A new oral suspension formulation of lamotrigine, this drug is indicated for the treatment of partial-onset seizures and bipolar disorder
Approval Date: Aug 2025
A GLP-1 receptor antagonist, this drug is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or who are overweight with at least one weight-related comorbidity. This is the first generically available GLP-1 receptor agonist for the treatment of obesity.
Approval Date: Jul 2025
A muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Approval Date: Jul 2025
An NSAID indicated for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
Approval Date: Jul 2025
Indicated alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension or coronary artery disease
Approval Date: Jul 2025
Indicated for the treatment of hypertension to lower blood pressure, in patients 55 and older to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, and in patients with post-myocardial infarction heart failure to reduce risk of death and hospitalization
Approval Date: Jul 2025
Indicated to improve glycemic control in patients with diabetes mellitus
Approval Date: Jun 2025
Indicated as an adjunct to diet and exercise to improve glycemic control for the treatment of type 2 diabetes
Approval Date: Jun 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns
Approval Date: May 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns. In March, a 2.5 mg dose of this generic was approved; this approval applies to 10 mg, 15 mg, and 20 mg doses
